Merck Serono and F-star Form Next-Generation Antibody Development Pact

By Heather Cartwright

Pharma Deals Review: Vol 2011 Issue 9 (Table of Contents)

Published: 19 Sep-2011

DOI: 10.3833/pdr.v2011.i9.1543     ISSN: 1756-7874

Section: Research & Development



F-star has signed a research, licence and commercialisation agreement with Merck Serono, potentially worth up to €492 M (US$692 M) for the discovery of novel monospecific Fc-based targeted biologics (Fcab™) and bispecific IgG-based targeted biologics (mAb² ™) against up to three inflammatory disease targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details